Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230922 | 0.76 | CHRNB2 (0.41) | GRM5KCNH2 | |
| SCHEMBL4807933 | 0.70 | GRM5 (0.96) | GRM5CYP1A2KCNH2 | |
| SCHEMBL4927688 | 0.68 | GRM5 (0.55) | GRM5CYP1A2KCNH2ALDH1A1MAPT | |
| SCHEMBL4862529 | 0.68 | GRM5 (0.62) | GRM5CYP1A2KCNH2ALDH1A1MAPT | |
| SCHEMBL352291 | 0.68 | GRM5 (0.65) | GRM5CYP1A2KCNH2 | |
| SCHEMBL6820640 | 0.66 | — | — | |
| SCHEMBL9853571 | 0.66 | CHRNA7 (0.50) | GRM5ALDH1A1MAPT | |
| SCHEMBL31673286 | 0.65 | GRM5 (0.58) | GRM5CYP1A2KCNH2MAPTHTT | |
| SCHEMBL31673207 | 0.65 | GRM5 (0.62) | GRM5CYP1A2KCNH2 | |
| Methyl Alcohol SCHEMBL28902013 | 0.64 | GRM5 (0.67) | GRM5CYP1A2KCNH2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1375496-B1 | N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | EISAI R&D MAN CO LTD (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7112593-B2 | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient | EISAI CO., LTD. (JP) | 2006-09-26 | — | — | US | disclosed |
| EP-1217001-B1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | EISAI CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-20040072830-A1 | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1375496-A1 | N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6599917-B1 | A squalene-synthesizing enzyme inhibitor, a cholesterol biosynthesis inhibitor and a triglyceride biosynthesis inhibitor | EISAI CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| EP-1217001-A1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072830-A1 | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient | COASY, HCCS, SQLE | GRM5 2205/4885CYP1A2 171/4885KCNH2 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.